Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome